Cagrilintide research
What PubMed holds on Cagrilintide, sorted by study design: the papers this site relies on, every clinical-trial publication PubMed tags, and the newest additions.
- PubMed records
- 121
- Trial publications
- 1515 randomized
- Reviews
- 65
- Human-subject tagged
- 76
- Animal-only
- 5
- Clinical-trial publications 15
- Reviews 65
- Animal-only studies 5
- Other (in vitro, chemistry, commentary, unindexed) 36
Studies this site relies on
Ordered by strength of design. Conclusions are quoted verbatim from each abstract as indexed by PubMed; read the full paper before relying on any of them.
-
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Garvey WT, Blüher M, Osorto Contreras CK, et al.
Cagrilintide-semaglutide provided significant and clinically relevant body-weight reductions in adults with overweight or obesity, as compared with placebo. (Funded by Novo Nordisk; REDEFINE 1 ClinicalTrials.gov number, NCT05567796.).
-
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Davies MJ, Bajaj HS, Broholm C, et al.
Once-weekly cagrilintide-semaglutide (at a dose of 2.4 mg each) resulted in a significantly lower body weight than placebo in adults with obesity and type 2 diabetes. (Funded by Novo Nordisk; REDEFINE 2 ClinicalTrials.gov number, NCT05394519.).
-
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Frias JP, Deenadayalan S, Erichsen L, et al.
In people with type 2 diabetes, treatment with CagriSema resulted in clinically relevant improvements in glycaemic control (including CGM parameters). The mean change in HbA1c with CagriSema was greater versus cagrilintide, but not versus semaglutide. Treatment with CagriSema resulted in significantly greater weight loss versus …
-
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Lau DCW, Erichsen L, Francisco AM, et al.
Treatment with cagrilintide in people with overweight and obesity led to significant reductions in bodyweight and was well tolerated. The findings support the development of molecules with novel mechanisms of action for weight management.
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
Enebo LB, Berthelsen KK, Kankam M, et al.
Concomitant treatment with cagrilintide and semaglutide 2·4 mg was well tolerated with an acceptable safety profile. Future larger and longer trials are needed to fully assess the efficacy and safety of this treatment combination.
Clinical-trial publications in PubMed
15 records carry PubMed’s clinical-trial publication type. Tagging is done by NLM indexers and occasionally includes secondary analyses.
Newest records
The most recent PubMed additions for this query at the data-edition date, regardless of design.
- Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy? Lancet · 2026 · Review
- Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding Physiol Behav · 2026 · Primary study
- Medical treatments for obesity: what does the future have in store? J Clin Endocrinol Metab · 2026 · Review
- Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3) Am Heart J · 2026 · Primary study
- CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis Front Endocrinol (Lausanne) · 2026 · Meta-analysis
- Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents Nutr Clin Pract · 2026 · Review
- Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs Pharmacol Res · 2026 · Review
- Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1 Diabetes Obes Metab · 2026 · Randomized trial
- New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus Diabetes Ther · 2026 · Review
- Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials Diabetes Metab Syndr Obes · 2026 · Primary study